Product Description
Mechanisms of Action: Gram+ Bacteria Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Vaginal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Ireland | Italy | Lebanon | Malaysia | Mexico | New Zealand | Pakistan | Philippines | Portugal | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Medinova AG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Vaginal Diseases|Vaginosis, Bacterial|Candidiasis, Vulvovaginal
Phase 3: Vaginosis, Bacterial|Vaginal Diseases|Gram-Positive Bacterial Infections|Pseudomonas Infections|Gram-Negative Bacterial Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MNFM380119 | P4 |
Terminated |
Vaginosis, Bacterial|Vaginal Diseases |
2022-08-25 |
|
2020-002489-15 | P4 |
Terminated |
Vaginosis, Bacterial |
2022-08-15 |
|
DEVA | P4 |
Unknown status |
Vaginosis, Bacterial |
2022-03-22 |
|
NCT04057482 | N/A |
Completed |
Vaginosis, Bacterial|Vaginal Diseases |
2017-12-01 |